Advanced search

Report side effect

Report a suspected side effect or falsified product to the MHRA Yellow Card scheme.
Go to {yellow_card_logo} site
{arrow_up} Back to top

Ponvory 2mg; 3mg; 4mg; 5mg; 6mg; 7mg; 8mg; 9mg; 10mg film coated tablets (treatment-initiation pack) {equilateral_black_triangle}

Active Ingredient:
ponesimod
Company:  
Janssen-Cilag Ltd (a Johnson & Johnson Company) See contact details
ATC code: 
L04AA50
{info_black}
About Medicine
{medical_services}
Prescription only medicine
Healthcare Professionals (SmPC) Patient Leaflet (PIL) Risk Materials Product Information HCP Med Info
{arrow_left}
{arrow_right}

Educational Risk Minimisation Materials to help reduce the risk associated with using this medicine.

{pdf_link}

Patient Caregiver Guide

This guide contains important information to ensure the safe and effective use of Ponvory and appropriately manage selected risks. Read this guide thoroughly before starting treatment.
{pdf_link}

Pregnancy Reminder Card

Information for female patients of childbearing potential.
{pdf_link}

Prescriber's Checklist

{healthcare_pro_orange} For Healthcare Professionals
This guide provides essential information on the most important identified and potential risks associated with Ponvory and the activities required to minimise these risks.

You are trying to reach document intended for healthcare professionals only.

Are you a healthcare professional?

Log in or sign up to avoid further verifications.

Janssen-Cilag Ltd (a Johnson & Johnson Company)
Company image
Address
50 - 100 Holmers Farm Way, High Wycombe, Bucks, HP12 4EG
Telephone
+44 (0)1494 567 567
Medical Information Fax
+44 (0) 1494 567 445
WWW
https://www.janssen.com/uk/
Fax
+44 (0)1494 567 568
Medical Information Direct Line
+44 (0)800 731 8450
Customer Care direct line
+44 (0)800 731 5550
Medical Information e-mail
[email protected]